Drug intelligence / Profile preview

ASP2713

Development stage: Discontinued
Lead developer: Astellas Pharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

ASP2713 is a novel anti-Igβ antibody with enhanced affinity for Fc gamma receptor (FcγR) IIB, developed by Astellas Pharma. It is designed to target B cells and has shown potential in treating systemic lupus erythematosus (SLE) by inhibiting antibody production and suppressing B cell proliferation. The drug acts as a CD32b antagonist.

Targets

B-cell antigen receptor complex-associated protein beta chainFCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on ASP2713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP2713.

Explore the full profile